key: cord-1031411-zgi8lim4 authors: Ippolito, Matthew M; Flexner, Charles title: Dose Optimization of Hydroxychloroquine for COVID-19: Do Blood Concentrations Matter? date: 2020-05-31 journal: Clin Infect Dis DOI: 10.1093/cid/ciaa691 sha: a9fe1ac0f429c8a559755f05e14a3388548ca79b doc_id: 1031411 cord_uid: zgi8lim4 nan recent National Institutes of Health guidelines for COVID-19 state that current data are insufficient to recommend for or against the use of HCQ or its predecessor chloroquine (CQ) [4] . Given the extraordinary times, clinicians the world over may reach for either drug in desperation. In this issue of Clinical Infectious Diseases, Perinel et al. and Martin-Blondel et al. present results of pharmacokinetic studies of HCQ with the intent of informing optimal dosing strategies for COVID-19 [5, 6] . Their intentions were sound. For most drugs, the concentration-response relationship is more informative than the dose-response relationship. Unfortunately, as has historically been the case with pharmacologic studies of HCQ, the current studies are bedeviled by the drug's extraordinary pharmacokinetics. In our 2018 paper in this journal [7] , we measured plasma concentrations of CQ, a structural analogue of HCQ with similar pharmacokinetics, using a validated liquid chromatography-tandem mass spectrometry assay, and concentrations were on the same order as those reported by Martin-Blondel et al. [6] . In all three studies there was a broad range of concentrations, as is often reported for HCQ and related compounds. Different sampling matrices (plasma, whole blood) yield highly discrepant measurements of HCQ, and it is from this observation that we can begin to pull back the curtain on the idiosyncratic pharmacokinetics of HCQ. This may consign the exercise at hand to uninterpretable outcomes. A c c e p t e d M a n u s c r i p t Applying pharmacokinetic methods to optimize drug dosing is the universally preferred approach for most drugs. The alternative approach, predating the advent of clinical pharmacokinetics in the 1960s, is allometric and empirical. Notably perhaps, HCQ was developed in this earlier era, still recognized for its extensive distribution throughout the body, and unequally so, with particular affinity for pigmented tissues and, important to note, lysosomes and other intracellular spaces [8] . HCQ is one of a small number of drugs for which the overwhelming driver of pharmacokinetics is volume of distribution (V d ) rather than clearance. The typical V d for HCQ is thousands to tens of thousands of liters for an average adult [9] . This imparts a long terminal elimination half-life, measured in weeks to months, despite relatively efficient renal and hepatic clearance. After a single 200 mg dose, HCQ remains detectable in urine for up to 3 months [10] . CQ, whose systemic pharmacokinetics are essentially indistinguishable from those of HCQ, remains detectable out to one year after the last dose of a typical malaria prophylaxis regimen [11] . HCQ's enormous V d is also the basis, in part, for the large interindividual variability in plasma and blood concentrations seen in the current studies, and is consistent with previous reports. Perinel et al. speculate, justifiably, that the pharmacokinetics might further be altered by the pathophysiology of COVID-19. Then there is the potential role of enantiomeric differences in tissue distribution and drug effect, seen in other indications [12] . It is no wonder CQ and HCQ have vexed generations of clinical pharmacologists. Because CQ and HCQ accumulate intracellularly, whole blood concentrations are several times higher than plasma concentrations and tend to be less variable patient-to-patient [12] . Whole blood is therefore the preferred matrix for pharmacokinetic studies of HCQ [12] . Higher concentrations make detection and quantitation easier, and using whole blood avoids the variability introduced into the assay during plasma separation. Blood concentrations are still a tiny sliver of a window into the presumed target tissues and cells for COVID-19 treatment and prevention. These would ostensibly be the type II pneumocytes of the alveoli, and other virally infected cells throughout the body, if one believes that HCQ has direct antiviral activity. End organ tissue concentrations can be hundreds of times greater than whole blood or plasma concentrations [13] . A c c e p t e d M a n u s c r i p t In contrast to COVID-19, malaria is principally an infection of red blood cells. Thus, pharmacokinetic sampling of the peripheral blood constitutes a tissue biopsy in malaria and therein provides a direct marker of the target compartment rather than a dubious stand-in. Despite this, in over half a century of research in malaria and rheumatologic diseases, studies of HCQ have found little to no correlation between drug concentrations and therapeutic response [14] [15] [16] . In addition to its abstruse pharmacokinetics, too little is known about HCQ pharmacodynamics to guide an appropriate dose optimization study design in COVID-19. The mechanism of HCQ's antiviral activity, if any, has not been elucidated. Also unknown are the pharmacokinetic/pharmacodynamic relationships between HCQ and severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), the etiologic agent of COVID-19, or between HCQ and the systemic inflammatory response, should it be the case that HCQ exerts a therapeutic effect by modulating host immunity. The site of action, if any, probably resides in the intracelluar compartment, but intracellular concentrations also have little to no discernable relationship to peripheral blood concentrations of HCQ [13] . If there were a clinically significant benefit of HCQ in COVID-19, is it concentration-or time-dependent? New models that account for target tissue pharmacokinetics suggest that HCQ regimens currently in clinical use and studied in clinical trials, some which approach safe dosing limits, may not reach maximal effect [17] . If those models hold, it would imply a narrow therapeutic window, all the more reason for exercising caution in moving forward with HCQ for COVID-19. Although less toxic than its predecessor CQ by design, serious neuro-and cardiotoxicities have been documented when HCQ plasma concentrations reach the range of 640 to 9,870 ng/mg [18] . A c c e p t e d M a n u s c r i p t More than a century ago, the grandfather of clinical pharmacology, Rudolph Bucheim, wryly observed that "a surgeon who uses the wrong side of the scalpel cuts [their] own fingers and not the patient; if the same applied to drugs they would have been investigated very carefully a long time ago." Despite generations of careful investigation, HCQ continues to evade easy study. Even under the best of circumstances, peripheral blood concentrations of HCQ are nearly impossible to interpret, and seeking therapeutically meaningful target concentrations is almost certainly bound to lead nowhere. Perhaps the lack of consensus around HCQ dosing strategies in ongoing clinical trials that motivated these two studies is for the best. If HCQ were to prove effective for COVID-19, we might arrive empirically at an optimized dosing regimen, which is likely to simply be the lowest effective dose. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection COVID-19) Treatment Guidelines: National Institutes of Health Hydroxychloroquine in COVID-19 patients: what still needs to be known about the kinetics Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients Effect of antiretroviral therapy on plasma concentrations of chloroquine and desethyl-chloroquine The treatment of acute malaria with single oral doses of amodiaquine, chloroquine, hydroxychloroquine and pyrimethamine Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications Bioavailability of hydroxychloroquine tablets in healthy volunteers Chloroquine excretion following malaria prophylaxis Clinical pharmacokinetics of slow-acting antirheumatic drugs Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine Response of Plasmodium falciparum to chloroquine treatment: relation to whole blood concentrations of chloroquine and desethylchloroquine Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing Treatment of hydroxychloroquine overdose A c c e p t e d M a n u s c r i p t